Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 110

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 110
---
 split of its issued Common Stock in the ratio of 1-for-1,500 (the “Reverse Stock Split”). As a result of the
Reverse Stock Split, the total number of shares of common stock held by each shareholder was converted automatically into the number of
whole shares of common stock equal to (i) the number of shares of common stock held by such shareholder immediately prior to the Reverse
Split, divided by (ii) 1,500, and then rounded up to the nearest whole number. No fractional shares were issued, and no cash or other
consideration was paid to any shareholder. Instead, the Company issued one whole share of the post-Reverse Stock Split common stock to
any shareholder who otherwise would have received a fractional share as a result of the Reverse Stock Split .Except for the Company’s
historical financial statements and unless otherwise stated, all option, share, and per share information gives effect to the Reverse
Stock Split.

E. DERIVATIVE LIABILITY

The Company analyzes the conversion feature of Convertible
Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion
features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The
embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement
period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the
change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scholes pricing model used to determine
the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2024
utilized the following inputs:

SCHEDULE OF DERIVATIVE LIABILITY ON CONVERTIBLE NOTES USING BLACK SCHOLES PRICING MODEL

| Schedule of Derivative liability       |     |          |     |
| Risk Free Interest Rate                |     |     4.59 | %   |
| Expected Term                          |     |     0.68 
 – (4.41) | Yrs |
| Expected Volatility                    |     |  1156.96 | %   |
| Expected Dividends                     |     |        - |     |
| Derivative Liability Measurement Input |     |        - |     |

F. INCOME TAXES

The Company accounts for income taxes using